Averin Capital Acquisition, a blank check company backed by Averin Capital targeting health and technology businesses, raised $250 million by offering 25 million units at $10. Each unit consists of one share of common stock and one-sixth of a warrant, exercisable at $11.50.
Averin Capital Acquisition is set to be led by Chairman and CEO David Berry, who in 2023 co-founded Averin Capital (fka Bedford Bridge), and has since served as its Managing Partner. He previously served as a General Partner at Flagship Pioneering, where he co-founded or helped build over 30 companies, including serving as co-founder and CEO of Valo Health. Berry is currently Chairman of Osler Diagnostics, and serves as a Director at Oaktree Acquisition III Life Sciences (OACCU), Hologen, Biolinq, and Salma Health. He is joined by CFO Alex Lau, who has served as the Partner and Head of Operations at Averin Capital since February 2025.
The New York, NY-based SPAC plans to target businesses at the intersection of technology and health. It states that it believes the health economy is in the process of being reshaped, creating an opportunity for cutting-edge companies to compete with and modernize legacy incumbents through breakthrough innovations and the application of technology, including artificial intelligence and automation.
Averin Capital Acquisition plans to list on the Nasdaq under the symbol ACAAU. Deutsche Bank acted as sole bookrunner on the deal. This is Deutsche's second SPAC IPO this year, after a more than three year hiatus, as more of the bulge bracket begins to re-enter the SPAC underwriting business.
